FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1981920830> ?p ?o ?g. }

• W1981920830 abstract "Background: The prognostic significance of CTC in metastatic, as well as in primary breast cancer has been demonstrated (Rack et al., ASCO 2010). The optimal endocrine treatment strategy for postmenopausal patients (pts) with hormone sensitive breast cancer remains unclear.We analyzed the prevalence of CTC two years after primary diagnosis in patients with tamoxifen or anastrozole treatment. Methods: As part of the translational research project of the German SUCCESS-trial, we analyzed 23ml of peripheral blood from 307 N+ and high risk N-postmenopausal pts with hormone sensitive breast cancer two years after adjuvant taxane based chemotherapy and with tamoxifen or anastrozole treatment. The presence of CTCs was assessed with the CellSearchSystem (Veridex, USA). After immunomagnetic enrichment with an anti-Epcam-antibody, cells were labelled with anti-cytokeratin (8,18,19) and anti-CD45 antibodies to distinguish between epithelial cells and leukocytes. Standard within the study was early switch treatment (tamoxifen for 2 years, followed by anastrozle), while pts with contraindications against tamoxifen were allowed to receive anastrozole up-front. Results: In 10.1% of pts (n=31) >1 CTC was detected after the completion of chemotherapy (range 2-33), while 7.8% (n=24) presented with >1 CTC (range 2-99) two years after completion of chemotherapy. The median age in the tamoxifen group was 59.9 years and 59.8 in the anastrozole group. In the tamoxifen group, 33.0% of the pts had a pT1 tumor, 5.3% G1 grading and 21.6% of the pts were node negative. In the anastrozole group, 30.0% of the pts had a pT1 tumor, 7.5% G1 grading and 22.5% of the pts were node negative, respectively. None of these differences were statistically significant. After the completion of chemotherapy, 9.7% of the pts were CTC positive in the tamoxifen group (range number of cells: 2-33) and 11.3% in the anastrozole group (range of cells: 2-24), p=0.69. Two years after primary diagnosis, 7.9% of the pts were CTC positive in the tamoxifen group (range number of cells:2-99) and 7.5% in the anastrozole group (range cells: 2-5), p=0.90. Actuarial disease free and overall survival will be presented at the meeting. Conclusions: The prognostic relevance of CTC in peripheral blood of early breast cancer patients both before and after chemotherapy has been demonstrated. The presented data will add information on the monitoring potential of CTC during adjuvant endocrine treatment. Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr PD04-08." @default.
• W1981920830 created "2016-06-24" @default.
• W1981920830 creator A5011557387 @default.
• W1981920830 creator A5013506154 @default.
• W1981920830 creator A5023254821 @default.
• W1981920830 creator A5024395879 @default.
• W1981920830 creator A5037914450 @default.
• W1981920830 creator A5048105827 @default.
• W1981920830 creator A5054111858 @default.
• W1981920830 creator A5059327156 @default.
• W1981920830 creator A5065612494 @default.
• W1981920830 creator A5073368077 @default.
• W1981920830 creator A5082681201 @default.
• W1981920830 creator A5089392438 @default.
• W1981920830 date "2010-12-15" @default.
• W1981920830 modified "2023-09-26" @default.
• W1981920830 title "Abstract PD04-08: Circulating tumor cells (CTC) in peripheral blood of breast cancer patients two years after adjuvant chemotherapy depending on endocrine treatment — The German SUCCESS-Trial" @default.
• W1981920830 doi "https://doi.org/10.1158/0008-5472.sabcs10-pd04-08" @default.
• W1981920830 hasPublicationYear "2010" @default.
• W1981920830 type Work @default.
• W1981920830 sameAs 1981920830 @default.
• W1981920830 citedByCount "0" @default.
• W1981920830 crossrefType "proceedings-article" @default.
• W1981920830 hasAuthorship W1981920830A5011557387 @default.
• W1981920830 hasAuthorship W1981920830A5013506154 @default.
• W1981920830 hasAuthorship W1981920830A5023254821 @default.
• W1981920830 hasAuthorship W1981920830A5024395879 @default.
• W1981920830 hasAuthorship W1981920830A5037914450 @default.
• W1981920830 hasAuthorship W1981920830A5048105827 @default.
• W1981920830 hasAuthorship W1981920830A5054111858 @default.
• W1981920830 hasAuthorship W1981920830A5059327156 @default.
• W1981920830 hasAuthorship W1981920830A5065612494 @default.
• W1981920830 hasAuthorship W1981920830A5073368077 @default.
• W1981920830 hasAuthorship W1981920830A5082681201 @default.
• W1981920830 hasAuthorship W1981920830A5089392438 @default.
• W1981920830 hasConcept C121608353 @default.
• W1981920830 hasConcept C126322002 @default.
• W1981920830 hasConcept C143998085 @default.
• W1981920830 hasConcept C2776215463 @default.
• W1981920830 hasConcept C2776694085 @default.
• W1981920830 hasConcept C2777176818 @default.
• W1981920830 hasConcept C2777511904 @default.
• W1981920830 hasConcept C530470458 @default.
• W1981920830 hasConcept C71924100 @default.
• W1981920830 hasConceptScore W1981920830C121608353 @default.
• W1981920830 hasConceptScore W1981920830C126322002 @default.
• W1981920830 hasConceptScore W1981920830C143998085 @default.
• W1981920830 hasConceptScore W1981920830C2776215463 @default.
• W1981920830 hasConceptScore W1981920830C2776694085 @default.
• W1981920830 hasConceptScore W1981920830C2777176818 @default.
• W1981920830 hasConceptScore W1981920830C2777511904 @default.
• W1981920830 hasConceptScore W1981920830C530470458 @default.
• W1981920830 hasConceptScore W1981920830C71924100 @default.
• W1981920830 hasLocation W19819208301 @default.
• W1981920830 hasOpenAccess W1981920830 @default.
• W1981920830 hasPrimaryLocation W19819208301 @default.
• W1981920830 isParatext "false" @default.
• W1981920830 isRetracted "false" @default.
• W1981920830 magId "1981920830" @default.
• W1981920830 workType "article" @default.